News in Brief: TSANZ welcomes new CEO; New indication for Xolair; Aboriginal patients have a higher bronchiectasis burden

Tuesday, 13 Apr 2021


TSANZ welcomes new CEO

Internationally renowned respiratory physiologist Dr. Graham Hall takes up the position after former incumbent Tanya Buchanan moved to Cancer Council Australia.

Dr Hall was former Deputy Director and Co-Head of Children’s Lung Health at Telethon Kids Institute in WA.

Aboriginal patients have a higher bronchiectasis burden 

A study from the Northern Territory illustrates the different ways bronchiectasis manifests itself among Australian Aboriginal and non-Aboriginal patients.

The analysis of 388 adults with radiology-confirmed bronchiectasis living in the subtropical Top End Health Service region of the NT in Australia found Aboriginal patients  were younger, had higher smoking rates, a greater prevalence of respiratory and non-respiratory co-morbidities, poorer lung function, more frequent exacerbations, and died at a younger age in compared to their non-Aboriginal counterparts.

“There is a clear and urgent need for feasible and effective interventions to reduce this inequity through primary prevention, improved delivery of existing therapies and the development and evaluation of new treatments,” the researchers concluded in their paper published in Rural and Remote Health.

New indication for Xolair

Omalizumab (Xolair) has received a new TGA listed indication as an add-on treatment for adults with severe chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids. The new indication is based on results from Phase III POLYP 1 and 2 studies.

 

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic